Analysis of the phase 2 part of IFCT-2103 DIAL
phase 2-3 randomised trial
Continuation pembrolizumab (± pemetrexed) up to 2 years versus observation (± pemetrexed), in patients with metastatic NSCLC with disease control at 6 months
Anne Claire Toffart (Grenoble, France)
Sunday, 25.10.2026
Rapid oral session (09:14 - 09:19)
Updated efficacy and safety results from the
IFCT-1904 ENCO-BRAF phase 2 trial
Encorafenib plus binimetinib in patients with BRAFV600E-mutant advanced NSCLC
Charles Ricordel (Rennes, France)
Monday, 26.10.2026
Poster (12:00 - 12:45)
Quality assurance of delineation and dosimetry of the
RTEP7-IFCT-1402 multicentre randomised phase II trial
Laura Haas (Rouen, France)
Monday, 26.10.2026
Poster (12:00 - 12:45)
